The U.S. Food and Drug Administration (FDA) initially approved the Fibrinogen on June 7, 2017

Fibrinogen is primarily used to treat individuals with documented fibrinogen deficiencies or dysfunctions. This therapy is crucial in various medical scenarios, including managing bleeding disorders such as congenital fibrinogen deficiencies, disseminated intravascular coagulation (DIC), and acquired hypofibrinogenemia. It is also employed during certain surgical procedures to control excessive bleeding, particularly when patients have impaired clotting function due to conditions like liver disease or major trauma. Additionally, it may be considered in specific obstetric situations, such as managing postpartum hemorrhage.

Fibrinogen can be administered through several routes, including intravenous (IV), intramuscular (IM), and in some cases, intraarterial (IA).  The healthcare provider determines the administration route based on the patient's needs and the urgency of treatment. 

The side effects of Fibrinogen  include allergic reactions (itching, hives, difficulty breathing, or swelling of the face, lips, tongue, or throat), transfusion reactions (acute hemolytic reactions, febrile non-hemolytic reactions), fluid overload, thrombosis (excessive blood clot formation), risk of transfusion-transmitted infections, hypersensitivity reactions in patients with known allergies,

Patients may experience allergic reactions, including itching, hives, difficulty breathing, or swelling of the face, lips, tongue, or throat. Transfusion-related reactions, such as acute hemolytic reactions (destruction of red blood cells), febrile non-hemolytic reactions (fever), and other adverse events, can occur during or after fibrinogen replacement. Administering large volumes of blood products can lead to fluid overload, particularly in patients with cardiac or renal conditions. There is a risk of excessive blood clot formation (thrombosis), especially in patients with underlying clotting disorders.

After taking Fibrinogen, patients should be monitored closely for signs of allergic reactions, such as itching, hives, difficulty breathing, or swelling of the face, lips, tongue, or throat. If any of these symptoms occur, immediate medical attention is required. Close monitoring is necessary to detect and manage transfusion reactions promptly. Patients with underlying clotting disorders should be carefully evaluated for excessive blood clot formation (thrombosis) risk.

It is essential to assess patients for allergies, potential allergic reactions, and underlying medical conditions like cardiovascular, liver, or kidney diseases, as these factors can impact fibrinogen. Medication interactions must be considered and adjusted accordingly, especially with anticoagulants or antiplatelet drugs. Thrombocytopenia, renal dysfunction, and multiple transfusions can affect treatment response and require close monitoring. Patients receiving human plasma should be informed of the minimal risk of viral transmission. 

1. KD Tripathi, Essentials of Medical Pharmacology, Drugs affecting coagulation, Bleeding and Thrombosis, 7th edition, 2013, 616.
2. Grifols UK Ltd, Electronic medicines compendium (EMC), [Revised on 4th August 2023] [Accessed on 8th September 2023], https://www.medicines.org.uk/emc/files/pil.5909.pdf
3. Octapharma USA Inc, US Food and Drug Administration, [Revised on Dec 2020] [Accessed on 8th September 2023], https://www.fda.gov/media/105864/download 

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.